Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-2A, Alpha-2C, Alpha-1B, and Alpha-1D adrenergic receptors (α2A, α2C, α1B, α1D)
- Target
- α2A, α2C, α1B, α1D
- Molecular classification
- G protein-coupled receptor (GPCR), Receptor
01
Overview
The alpha-adrenergic receptor subtypes α2A, α2C, α1B, and α1D are members of the G protein-coupled receptor superfamily that respond to catecholamines including noradrenaline and adrenaline. They regulate critical processes like vascular tone, smooth muscle contraction, neurotransmitter release, and central nervous system function. Although structurally related, each subtype differs in tissue localization, physiological roles, and drug selectivity. Drugs targeting these receptors are used to treat cardiovascular, urologic, and neuropsychiatric conditions, with therapeutic challenges including subtype-selective modulation and risk of systemic side effects.
- Other names
- Alpha-adrenergic receptor subtypesadrenoceptor alpha 2A/C, alpha 1B/D
02
Mechanism of action
Agonists mimic catecholamines, activating the receptors to induce vasoconstriction, reduce sympathetic tone, or modulate neurotransmitter release; Antagonists block catecholamine action, causing vasodilation, lowering blood pressure, or relaxing smooth muscle
03
Biological functions
Signal transductionRegulation of neurotransmitter releaseVasoconstriction and blood pressure controlSmooth muscle contractionInhibition or facilitation of neurotransmitter release (subtype-dependent)
04
Disease associations
Cardiovascular disease (hypertension, heart failure, shock)Benign prostatic hyperplasiaNeuropsychiatric disorders (depression, anxiety, PTSD)Urological disordersOther roles depending on tissue localization and subtype
05
Safety considerations
Hypotension (with antagonists)Hypertension and bradycardia (with agonists)SedationDry mouthDizzinessRisk of syncopeSubtype-specific adverse effects, such as urinary retention (α1 antagonists) or CNS depression (α2 agonists)
06
Interacting drugs
Clonidine (α2A)
9 more in the full profile.
07
Biomarkers
Blood pressure (for pharmacodynamic monitoring)Plasma norepinephrine/epinephrineUrinary catecholaminesLimited molecular biomarkers for patient selection at present
Beyond the preview
Go deeper on Alpha-2A, Alpha-2C, Alpha-1B, and Alpha-1D adrenergic receptors (α2A, α2C, α1B, α1D).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpha-2A, Alpha-2C, Alpha-1B, and Alpha-1D adrenergic receptors (α2A, α2C, α1B, α1D).